Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15714425.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculous therapy. Physicians should be aware of the increased risk of a paradoxical response in this population and should consider the use of corticosteroids when a paradoxical reaction is suspected.
Medical subject headings
- Antibodies, Monoclonal
- Antitubercular Agents
- Tuberculosis, Pulmonary